20 21 2 CRISPR-Cas9 gene editing technology is derived from a microbial adaptive 22 immune system, where bacteriophages are often the intended target. Natural 23 inhibitors of CRISPR-Cas9 enable phages to evade immunity and show promise 24 in controlling Cas9-mediated gene editing in human cells. However, the 25 mechanism of CRISPR-Cas9 inhibition is not known and the potential 26 applications for Cas9 inhibitor proteins in mammalian cells has not fully been 27 established. We show here that the anti-CRISPR protein AcrIIA4 binds only to 28 assembled Cas9-single guide RNA (sgRNA) complexes and not to Cas9 protein 29 alone. A 3.9 Å resolution cryo-EM structure of the Cas9-sgRNA-AcrIIA4 complex 30 revealed that the surface of AcrIIA4 is highly acidic and binds with 1:1 31 stoichiometry to a region of Cas9 that normally engages the DNA protospacer 32 adjacent motif (PAM). Consistent with this binding mode, order-of-addition 33 experiments showed that AcrIIA4 interferes with DNA recognition but has no 34 effect on pre-formed Cas9-sgRNA-DNA complexes. Timed delivery of AcrIIA4 into 35 human cells as either protein or expression plasmid allows on-target Cas9-36 mediated gene editing while reducing off-target edits. These results provide a 37 mechanistic understanding of AcrIIA4 function and demonstrate that inhibitors 38 can modulate the extent and outcomes of Cas9-mediated gene editing. 39 40 41
3
Phage-encoded inhibitors of CRISPR-Cas bacterial immune systems evolved to enable 42 phage escape from destruction in bacterial cells (1) and have the potential to control 43 CRISPR-Cas enzymes that are deployed for gene editing applications in various cell 44 types (2, 3). Determination of the molecular basis for Cas9 inhibition could shed light on 45 the evolutionary "arms race" between phage and bacteria, as well as suggest new 46 approaches to regulate genome editing in eukaryotic cells. The 87 amino acid anti-47 CRISPR-Cas9 protein AcrIIA4 is notable in both respects: it inhibits multiple Cas9 48 proteins including the widely used Cas9 ortholog from Streptococcus pyogenes (Spy), 49
and it blocks Cas9-mediated gene editing in human cells (3). To investigate the 50 molecular basis for AcrIIA4-mediated Cas9 inhibition, we first tested whether 51 recombinant AcrIIA4 protein interacts directly with SpyCas9 ( Fig. 1A) . Purified AcrIIA4 52 was incubated with SpyCas9 in the presence or absence of a single-guide RNA 53 (sgRNA) that assembles with Cas9 to provide sequence-specific DNA recognition (4). 54
Size exclusion chromatography showed that AcrIIA4 binds to SpyCas9 only in the 55 presence of sgRNA ( Fig. 1B and C, fig. S1 ), implying that AcrIIA4 recognizes a protein 56 surface created upon sgRNA-triggered conformational rearrangement (5, 6) . 57 Furthermore, the AcrIIA4-bound Cas9-sgRNA complex is more resistant to proteolytic 58 digestion than the Cas9-sgRNA complex alone, implying that AcrIIA4 stabilizes a 59 particular Cas9 conformation ( fig. S2 ). 60
To elucidate the molecular basis of AcrIIA4-mediated inhibition of Cas9 activity, 61
we performed cryo-electron microscopy (cryo-EM) single-particle analysis on a 62
SpyCas9-sgRNA complex bound to AcrIIA4. Cryo-EM images were collected on a Krios 63 microscope using zero-loss energy-filtered imaging and a K2 direct electron detector. 64
After unsupervised 3D classification of 840,000 particle images, refinement of a class 65 containing 285,600 particles resulted in an EM reconstruction of the SpyCas9-sgRNA-66
AcrIIA4 complex with an overall resolution of 3.9 Å ( fig. S3-S4 ). Subsequent local 3D 67 classification that was focused on Cas9's HNH nuclease domain ultimately yielded two 68 EM reconstructions, one at 3.9 Å resolution where the HNH was poorly resolved due to 69 flexibility (reconstruction 1, obtained as a combination of two 3D classes) ( Fig. 2a and S3). In both cryo-EM reconstructions, the density for the HNH domain of Cas9 was 73 weaker than for the rest of the structure, consistent with the previously observed 74 conformational plasticity of the HNH nuclease domain in the pre-targeting state. An 75 atomic model for AcrIIA4 was built from reconstruction 1. The EM density map displays 76 excellent main-chain connectivity and side-chain densities for almost all residues of 77 AcrIIA4 ( fig. S5 ). We then built an atomic model for the Cas9-sgRNA complex based on 78 the crystal structure of SpyCas9-sgRNA (PDB ID 4ZT0) and refined the entire SpyCas9-79 sgRNA-AcrIIA4 model in real space to good stereochemistry ( Fig. 2B and table S1). 80
Overall, Cas9 bound to AcrIIA4 resembles the pre-target state rather than the DNA-81 bound state ( fig. S6) . 82
De novo model building demonstrated that AcrIIA4 binds to Cas9 with 1:1 83 stoichiometry and comprises a three-stranded antiparallel β sheet flanked by one alpha-84 helix at the amino-terminal end and two α helices on the carboxy-terminal end 85 (α 1 β 1 β 2 β 3 α 2 α 3 ). Remarkably, superposition of the AcrIIA4-bound Cas9 structure with 86 DNA-bound Cas9 revealed that AcrIIA4 sits exactly in the PAM-interacting cleft formed 87 between the alpha-helical recognition (REC) lobe and the nuclease lobe ( Fig. 2B and  88 fig. S6). AcrIIA4 completely occupies the PAM binding pocket and thus blocks DNA 89 recognition through contacts between the β3 strand of AcrIIA4 and Cas9 PAM-binding 90 residues (R1333 and R1335) ( Fig. 2D-E ). In addition, AcrIIA4 wedges into the DNA 91 melting region immediately upstream of the PAM sequence and sits on top of +1 92 phosphate on the target strand and the flipped nucleotides on the nontarget strand, 93
indicating AcrIIA4 could also prevent DNA binding/unwinding. Consistent with this DNA-94 mimicing binding mode, AcrIIA4 is extremely acidic ( Fig. 2E ). Interestingly, AcrIIA4 also 95 occupies the same space as the DNA-bound HNH domain and the linker connecting the 96 HNH and RuvC domains ( Fig. 2D ), suggesting AcrIIA4 could block the HNH movement 97 required for catalysis ( Fig. 2B, C) . 98
Collectively, our structural studies show that AcrIIA4 is a highly acidic DNA mimic 99 that blocks target DNA recognition through multiple mechanisms: 1) competitive 100 inhibition of PAM binding; 2) inhibition of DNA unwinding upstream of the PAM 101 sequence; and 3) inactivation of HNH domain movement from the inactive to active 102 conformation. These structural findings help explain the effectiveness of AcrIIA4 as an 103 inhibitor of Cas9-mediated DNA cleavage and cell-based genome editing. Previous 104 studies revealed the importance of Cas9's interactions with targeted DNA, mediated via 105 the PAM in an interaction preceding base pairing between the sgRNA and its target (7). 106
Transient Cas9-sgRNA association with PAM sequences in DNA is thought to enable a 6 rapid target sequence search. By mimicking the structure and electrostatic properties of 108 the DNA PAM sequence, AcrIIA4 might compete for initial DNA binding and thereby 109 prevent target recognition and cleavage ( Fig. 2E-G) . 110
To determine the functional effects of AcrIIA4 binding to Cas9-sgRNA 111 complexes, we subjected DNA substrates possessing a target sequence to Cas9-112 sgRNA-catalyzed DNA cleavage assays. A linearized plasmid possessing a target 113 sequence and PAM was incubated with combinations of Cas9, sgRNA and AcrIIA4, and 114 the products were resolved by gel electrophoresis. Cas9-sgRNA alone completely cut 115 the target DNA within five minutes, while AcrIIA4 limited cleavage at even later time 116 points ( Fig. 3A ). To confirm that AcrIIA4 would also inactivate Cas9 at low enzyme and 117 inhibitor concentrations, we performed similar experiments with a radiolabeled DNA 118 target for increased sensitivity (Fig. 3B ). Near-stoichiometric concentrations of AcrIIA4 119 inhibited DNA cleavage when titrated against 10 nM Cas9-gRNA complex, indicating an 120 apparent dissociation constant of less than 10 nM. These data show that AcrIIA4 121 functions as a robust Cas9 "off-switch" that can inhibit most Cas9 activity at low 122
concentrations. 123
The structure of Cas9 bound to AcrIIA4 suggested that the inhibitor competes for 124 the initial DNA recognition event of PAM binding. Yet we previously found that Cas9 125 binds so tightly to target DNA that its off-rate is negligible (7, 8) . This implies an unusual 126 non-equilibrium mode of inhibition, in which AcrIIA4 requires access to Cas9-sgRNA 127 prior to formation of the Cas9-sgRNA-DNA complex. To test this prediction, we used 128 bilayer interferometry to measure the binding of catalytically inactivated Cas9 (dCas9) to 7 a DNA target in the presence of inhibitor. These experiments were performed under 130 stoichiometric binding conditions in which Cas9 was present at concentrations greater 131 than the dissociation constant of the Cas9-AcrIIA4 interaction. Pre-incubation of Cas9 132 with AcrIIA4 markedly inhibited Cas9 binding to DNA (on-rate) in a dose-dependent 133 fashion, including complete prevention of target engagement (Fig. 3C, fig. S7 ). An 134 electrophoretic mobility shift assay (EMSA) further confirmed that AcrIIA4 does not 135 impact sgRNA loading into Cas9 protein alone ( fig. S8 ), but does inhibit Cas9-sgRNA 136 complex binding to a target DNA ( fig. S9 ). Strikingly, allowing the Cas9-sgRNA-DNA 137 complex to form and then adding AcrIIA4 had no effect on Cas9's release of target DNA 138 (off-rate). These order-of-addition results are consistent with both the structure of 139 AcrIIA4 bound to Cas9 and Cas9's extremely slow dissociation from DNA. Together, 140 these data support a mechanism for AcrIIA4 inhibition in which the inhibitor blocks 141 fig. S10 , S11). This implied that the order-of-addition effects we observed in 152 biophysical experiments may play a role during gene editing. To test this idea, we 153 nucleofected AcrIIA4 plasmid 24 hours prior to introducing Cas9 RNP into cells. The 154 presence of the AcrIIA4-encoding plasmid 24 hours prior to Cas9 RNP introduction 155 inhibited Cas9-mediated gene targeting to a far greater extent than was observed 156 during co-introduction, and to a similar extent as observed during co-introduction of 157
AcrIIA4 protein and Cas9 RNP (Fig. 4B, fig. S12 ). Remarkably, we found that addition of 158 AcrIIA4 six hours after Cas9-RNP reduced editing by ~50%, demonstrating the utility of 159 inhibitors for revealing in vivo gene editing kinetics (Fig. 4C, fig. S13 ). In sum, 160 controlling the timing of AcrIIA4 inhibition in human cells strongly affects the frequency 161 of gene editing at a given locus. 162
Using a given guide RNA, Cas9 may target both an on-target site and off-target 163 loci (9-12). But several lines of evidence suggest that off-target sites may be bound 164 without being immediately cleaved (13-15). Cas9 displaced from uncleaved sites (e.g. 165 by cellular factors) would be available for inhibition by AcrIIA4. Since inhibitor timing 166 experiments suggested that at least 50% of on-target Cas9 gene editing takes place 167 within the first 6 hours (Fig. 4C) , we asked whether off-target editing could be reduced 168 by properly timed addition of inhibitor. 169
We examined on-and off-target editing using guide RNAs targeting the EMX1 170 and HBB loci. The off-target sites for both the EMX1 and HBB guides have been 171 previously described (10, 16, 17) . Notably, the HBB guide is of therapeutic interest to 172 edit the causative mutation of sickle cell disease, but has an off-target that is nearly 9 identical to the on-target site. We edited the EMX1 and HBB loci using Cas9 RNPs with 174 and without pre-introduction of AcrIIA4 protein or plasmid. Consistent with experiments 175 at the BFP locus, we found that timed addition of AcrIIA4 retained substantial levels of 176 on-target editing. Strikingly, both T7E1 and TIDE analysis showed that timed addition of 177
AcrIIA4 almost completely abolished off-target editing at both HBB and EMX1 (Fig. 4D) . 178
This suggests that Cas9 inhibitors have the potential to be useful in reducing off-target 179 events during research and therapeutic applications. 180
The recent and rapid expansion of the Cas9 toolkit for gene editing applications 181 has lacked an inducible "off-switch" to prevent undesired gene editing. Newly 182 discovered protein inhibitors, encoded by bacteriophages, provide an attractive solution 183
to this problem as these proteins are small and function well in human cells (3). Here, 184
we demonstrate that AcrIIA4, the most potent SpyCas9 inhibitor in human cells, acts as 
